Inhibition of osteogenesis in vitro by a cigarette smoke-associated hydrocarbon combined with Porphyromonas gingivalis lipopolysaccharide: reversal by resveratrol.
BACKGROUND
Smoking and infection with Gram-negative bacterial pathogens are risk factors for alveolar bone loss. The aims of this study were: 1) to examine the combined effects of an aryl hydrocarbon, benzo[a]pyrene (BaP), that is concentrated in cigarette smoke, and lipopolysaccharide (LPS) extracted from Porphyromonas gingivalis on osteogenesis in a rat bone marrow cell (RBMC) model of osteogenesis; and 2) to determine whether resveratrol (Res), an aryl hydrocarbon receptor antagonist, could reverse the putative inhibitory effects of BaP + LPS on osteogenesis.


METHODS
LPS of P. gingivalis strain 2561 was introduced in various concentrations to the RBMC in 96-well plates and kept in culture for 8 to 12 days. The same protocol was used for studying BaP and LPS + BaP combinations. Following the incubation periods, parameters of osteogenesis were measured, including formation of mineralized bone nodules, alkaline phosphatase activity, and total cell protein. Transcription of the pro-inflammatory cytokine interleukin (IL)-1beta in the cultures was determined by reverse transcriptase polymerase chain reaction (RT-PCR).


RESULTS
Bone nodule formation generally decreased significantly with increasing LPS concentrations (P<0.05), whereas total cell protein decreased only slightly (P>0.05). BaP in previously high concentrations alone also caused a significant dose-dependent decrease in bone nodule formation (P<0.05) but when half maximal doses were used, significant decreases were most often seen when LPS was added. Hence, in combination, the inhibitory effects of LPS + BaP on osteogenesis were additive, inhibiting bone nodule formation up to 9-fold. Resveratrol partially reversed the inhibitory effects of low concentrations of LPS alone, and completely reversed the inhibition of nodule formation when low concentrations of LPS were combined with BaP. IL-1beta expression generally fluctuated inversely to the inhibitory activity of LPS, LPS + BaP, and LPS + BaP + Res combinations.


CONCLUSIONS
Smoke-derived aryl hydrocarbons and bacterial LPS may act additively to inhibit bone formation. The findings may explain, in part, why net periodontal bone loss is greater and bone healing is less successful in smokers than non-smokers with periodontal infections. Reversal of the inhibitory effects in vitro by resveratrol suggests that this phytoalexin should be studied further for its potential therapeutic value, given its aryl hydrocarbon receptor antagonism and apparent anti-inflammatory activity.
Andreou
V
V
Graduate Program in Periodontology, Graduate Department of Dentistry, Canadian Institutes of Health Research Group in Matrix Dynamics, University of Toronto, University Health Network, Toronto, ON.
D'Addario
M
M
Zohar
R
R
Sukhu
B
B
Casper
R F
RF
Ellen
R P
RP
Tenenbaum
H C
HC
D016301:Alveolar Bone Loss / Q000209:etiology / Q000517:prevention & control*; D000818:Animals; D001564:Benzo(a)pyrene / Q000037:antagonists & inhibitors / Q000633:toxicity*; D002478:Cells, Cultured; D004357:Drug Synergism; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000633:toxicity*; D008297:Male; D010012:Osteogenesis / Q000187:drug effects*; D016966:Porphyromonas gingivalis; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012906:Smoke; D013267:Stilbenes / Q000627:therapeutic use*; D014026:Nicotiana
D008070:Lipopolysaccharides; D012906:Smoke; D013267:Stilbenes; D001564:Benzo(a)pyrene; D000077185:Resveratrol